Quick Answer
Creatine Older Adults Cognition Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: These changes contribute to increased sarcopenia risk during and after the menopausal transition, with implications for physical function, frailty, and long-term musculoskeletal health [].
Key Takeaways
- 01These changes contribute to increased sarcopenia risk during and after the menopausal transition, with implications for physical function, frailty, and long-term musculoskeletal health []. [Naddafha Siavash (2026)]
- 02In addition, creatine may exert direct anabolic or anticatabolic effects on muscle cells and influence bone via increased muscle pulling forces or direct cell signaling in osteoblasts []. [Naddafha Siavash (2026)]
- 03For example, a 12-week RCT reported that creatine (5 g/day) with RT significantly increased muscle strength and fat-free mass in women aged ~65 years []. [Naddafha Siavash (2026)]
- 041 2 3 4 5 6 6 Muscle and bone loss accelerate during the postmenopausal years due to aging and estrogen deficiency. [Naddafha Siavash (2026)]
The current Migaku evidence database contains 2 reusable source documents for Creatine Older Adults Cognition Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- These changes contribute to increased sarcopenia risk during and after the menopausal transition, with implications for physical function, frailty, and long-term musculoskeletal health []. [Naddafha Siavash (2026); evidence level 1]
- In addition, creatine may exert direct anabolic or anticatabolic effects on muscle cells and influence bone via increased muscle pulling forces or direct cell signaling in osteoblasts []. [Naddafha Siavash (2026); evidence level 1]
- For example, a 12-week RCT reported that creatine (5 g/day) with RT significantly increased muscle strength and fat-free mass in women aged ~65 years []. [Naddafha Siavash (2026); evidence level 1]
- 1 2 3 4 5 6 6 Muscle and bone loss accelerate during the postmenopausal years due to aging and estrogen deficiency. [Naddafha Siavash (2026); evidence level 1]
- 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). [Wang Xiaolan (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources